| Authors: |
Cleary JM; Dana-Farber Cancer Institute, Boston, MA., Springfeld C; Heidelberg University Hospital, Heidelberg, Germany., Arnold D; Asklepios Klinik Altona, Hamburg, Germany., Hollebecque A; Gustave Roussy, Villejuif, France., Gbolahan O; Emory Winship Cancer Institute, Atlanta, GA., Nagasaka M; University of California Irvine School of Medicine, Orange, CA., Siena S; Department of Hematology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Opdam F; Netherlands Cancer Institute, Amsterdam, The Netherlands., Sunakawa Y; St Marianna University Hospital, Kawasaki, Japan., Cassier PA; Centre Léon Bérard, Lyon, France., Trikha G; Cancer Specialists of North Florida, Jacksonville, FL., Gort EH; Universitair Medisch Centrum Utrecht, Utrecht, The Netherlands., Florou V; Huntsman Cancer Institute, Salt Lake City, UT., Greil R; Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, Salzburg, Austria.; Paracelsus Medical University, Salzburg, Austria., La Porte PF; The Oncology Institute of Hope and Innovation-Long Beach, Cerritos, CA., Gandhi PJ; Partner Therapeutics, Inc, Lexington, MA., Garner F; Partner Therapeutics, Inc, Lexington, MA., Wasserman E; Merus, Cambridge, MA., Adeyemi S; Merus, Cambridge, MA., Schram AM; Memorial Sloan Kettering Cancer Center, New York, NY. |
